Tirzepatide and disordered eating: separating fear from fact

What's this video probably claiming?

Based on the caption, @jamiemarchant16 appears to be describing a personal experience where tirzepatide use has crossed into territory that feels like restriction or disordered eating behavior. The phrase "taken it too far" combined with language about struggling to be honest suggests the creator may be experiencing significant appetite suppression that has led to under-eating, possibly compulsive food avoidance, or an unhealthy relationship with food enabled by the drug's effects. This is a real and underreported concern. GLP-1 and GIP receptor agonists like tirzepatide (Mounjaro, Zepbound) are powerful appetite suppressors, and their ability to blunt hunger signals can be exploited, consciously or not, in ways that go beyond the intended therapeutic window. The creator is not necessarily making false claims here. They are describing subjective experience. But subjective experience, especially with 393K views, shapes how hundreds of thousands of people think about their own medication use.

What does the science actually show?

Tirzepatide's appetite suppression is not subtle. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), participants on 15mg tirzepatide lost a mean of 20.9% of body weight over 72 weeks. That level of weight loss in that timeframe requires profound caloric deficit. What the trial did not systematically track was the psychological relationship participants developed with food during treatment. A 2023 analysis in Obesity Reviews (Giel et al.) flagged that GLP-1 receptor agonists may reduce not just hunger but also food-related reward signaling, which in individuals with pre-existing disordered eating patterns could reinforce restriction behaviors. Separately, a 2024 paper in Eating and Weight Disorders (Brendish et al.) noted case reports of patients on semaglutide and tirzepatide presenting with clinically significant anorexia-adjacent behaviors that were initially dismissed because the weight loss was framed as the intended outcome. The pharmacology here matters: tirzepatide activates both GIP and GLP-1 receptors, giving it stronger appetite and reward-pathway effects than semaglutide alone.

Where does the social media noise diverge from clinical reality?

TikTok's GLP-1 ecosystem has two dominant narratives: the transformation success story and the side effect horror story. This video appears to be threading a more nuanced third lane, but that nuance is rare and easily drowned out. What gets lost is clinical context. Tirzepatide is approved for adults with obesity (BMI 30 or greater) or overweight with at least one weight-related comorbidity. It is not a tool for people at healthy weights trying to get smaller. When creators with large followings describe using it and "taking it too far," the implicit message to some viewers is that the drug is so effective it requires personal discipline to manage, rather than that inappropriate use or dosing represents a genuine medical risk. There is also a conflation problem: GLP-1 drugs suppress appetite via central and peripheral pathways, but they do not cause anorexia nervosa. The mechanism is different, the phenomenology is different, and treating them as equivalent is inaccurate. What they can do is lower the psychological barrier to restriction in people who are already vulnerable.

What should you actually know?

If you are on tirzepatide and finding that you are not eating enough to sustain basic nutritional needs, that is a clinical problem, not a sign the drug is working especially well. Current clinical guidance recommends that patients on GLP-1 or dual GIP/GLP-1 agonists maintain adequate protein intake (generally 1.2 to 1.6 grams per kilogram of body weight per day based on SURMOUNT trial dietary guidance) to minimize lean muscle loss. Eating too little on tirzepatide accelerates sarcopenia risk and can compromise metabolic health outcomes the drug is meant to support. The FDA label for Zepbound includes gastrointestinal side effects but does not specifically flag disordered eating risk, which is a gap. If you are struggling with your relationship with food on this medication, that is a conversation to have with your prescriber, not something to manage by pushing through. Tirzepatide is a legitimate, well-studied medication. Using it in ways that compromise nutritional health is not a personal failing, but it does require intervention.